Literature DB >> 27844019

Analysis of IL-33 gene polymorphism (rs11792633 C/T) and risk of schizophrenia.

Dor Mohammad Kordi-Tamandani1, Ahmad Reza Bahrami2, Raziye Sabbaghi-Ghale-No2, Hanieh Soleimani1, Tayebe Baranzehi1.   

Abstract

Recently, inflammation has been found to be a significant factor in the development of Schizophrenia (SCZ). The aim of the present research was to investigate whether interleukin-33 (IL-33, OMIM: 608678) gene polymorphism (rs11792633, C/T) is associated with the development of SCZ or not. DNA was isolated from the serum of 70 patients with SCZ and 70 healthy controls. The PCR based method was used for detection of the IL-33 polymorphism. The CT (OR=0.05, 95% CI: 0.003-0.057, P<0.001) and TT (OR=0.12, 95% CI: 0.028-0.46, P<0.001) genotypes significantly decreased the risk of SCZ. Our present findings indicate that the IL-33 polymorphism associated with the risk of SCZ.

Entities:  

Keywords:  IL-33; Polymorphism; Schizophrenia

Year:  2016        PMID: 27844019      PMCID: PMC5019332     

Source DB:  PubMed          Journal:  Mol Biol Res Commun        ISSN: 2322-181X


INTRODUCTION

Schizophrenia (SCZ) is a genetically complex mental disorder, which may affect up to 1% of the world’s population. There is some evidence suggesting that cytokine production during chronic activation of the immune system ,which is observed in SCZ, could modulate prodromes, the active residual phases of this disease, and influence response to treatment [1, 2]. Interleukin-33 (IL-33, OMIM: 608678) is a 30kD protein with a length of 270 amino acids in two domains, a helix-turn-helix domain and an IL-1-like domain for binding to and activation of the ST2 receptors [3, 4]. IL-33 can act as either a pro-inflammatory or an anti-inflammatory cytokine [4-6]. Recently it has been described as a member of the IL-1 family. This cytokine has a dual-function with nuclear and extracellular effects [4]. The critical role of this cytokine in allergic inflammatory diseases such as rhinitis is well known [6]. IL-33 is a ligand of the IL-1R family member ST2 (also called ST2L, T1, Der-4), which makes part of the Toll-like receptor (TLR)/IL1R super family [7]. The producers of IL-33 are different immune cells such as macrophages, dendritic cells and mast cells (in these cells, IL-33 induces the secretion of chemokines and cytokines such as IL-6, IL-8, and IL-13). In addition, some of the non-immune cells including endothelial, epithelial, smooth muscle cells and fibroblasts are producers of this cytokine [8]. Basal IL-33 mRNA levels are extremely high in the brain and spinal cord. Furthermore, the expression of IL-33 in glial and astrocyte cultures is increased by Toll-like receptor ligands. Treatment with IL-33 induces the proliferation of microglia and enhances the production of pro-inflammatory cytokines such as IL-1b and TNFα as well as the anti-inflammatory cytokine IL-10. It also enhances chemokines, along with nitric oxide production and phagocytosis by microglia [9]. A better understanding of the molecular events that occur during inflammation within the central nervous system could lead to the development of novel therapeutic strategies to treat disorders associated with activation of inflammatory pathways in the brain. The aim of the present study was to determine the association of IL-33 gene polymorphism (rs11792633, C/T) with the development of SCZ.

MATERIALS AND METHODS

This case-control study was approved by the Ethics Committee of Azadi Hospital, Tehran, Iran and conducted in 2010–2011. The subjects consisted of a healthy control group (n=70), who were free from any signs of neuropsychiatric diseases, and a patient group diagnosed with SCZ (n=70). Serum samples for DNA extraction were collected in tubes. For DNA extraction, a Cinnapure DNA purification kit was used. Polymorphism was identified by PCR using a Tetra Amplification Refractory Mutation System (Tetra ARMS–PCR). Sequences of primers used are listed in Table 1.
Table 1

Primers sequences and annealing temperatures for rs11792633 polymorphism

Primer typeOrientationPrimer Sequence(5ʹ3ʹ)Tm (ᵒC)
Outer primersForwardTGCTTGTCCTACTAGATGCTAGCCCCCACA72
Reverse GCATGATTTTGGTGGAAACATTCAAACCA72
Inner primersForwardCCCAGAGTCCACACTCAGTATTAGGCAGG72
ReverseTAGTCAGCATCACATGGGAACGTGATCGA73
Primers sequences and annealing temperatures for rs11792633 polymorphism Statistical analysis was conducted using SPSS statistical software, version 16 (SPSS, Chicago, IL) and Epical version3.2. Categorical data were analyzed by Pearson’s x2 test.

RESULTS AND DISCUSSION

The main characteristics of the populations are described in Table 2. There were differences between cases and controls for smoking habit, educational levels, and marital status.
Table 2

The socio-demographic characteristics of the case and control groups

Variable Cases Controls P
Age 47.5+10.846.7+11.7>0.05
Age of onset 20.7+8.7--
Sex
Females 3044>0.05
Males 4026
Smoking status
Non smokers -45<0.001
Smokers 7025
Educational level
Illiteracy 3-
Primary School 81
Guidance 165<0.001
High school 5428
Marital status
Single 5029
Married 1741<0.001
Divorced 166
As shown in Table 3, CT (OR=0.05, 95% CI: 0.003-0.057, P<0.001) and TT (OR=0.12, 95% CI: 0.02-0.46, P<0.001) genotypes significantly decreased the risk of SCZ. Studies have revealed that one of the abnormalities found in SCZ includes changes in the immunological system [10].
Table 3

Association between polymorphism of IL-33 rs11792633 C/T) and risk of schizophrenia

Genotypes Cases (%) Controls (%) OR 95% CI P
CC41 (58.5) 4 (5.7) 1.0--
CT7 (10.0) 49 (70.0) 0.05 0.003-0.057 <0.001
TT22 (31.4) 17 (24.2) 0.120.028-0.46 <0.001
CT+TT29660.040.01-0.13 <0.001
The socio-demographic characteristics of the case and control groups Association between polymorphism of IL-33 rs11792633 C/T) and risk of schizophrenia We hypothesized that patients with SCZ may demonstrate a different distribution of allele frequencies in the IL-33 gene from controls. In this study, we have reported the significant association of rs11792633 SNP in the IL-33 and risk of SCZ in an Iranian population. IL-33 may also play a protective role in the development and progression of atherosclerosis [12]. Recently, functional studies have shown that the minor alleles, rs1157505, rs11792633, and rs7044343 within IL-33 were associated with a lower degree of cerebral amyloid angiopathy in the brains of non- apolipoprotein E, and IL-33 expression was reduced in the brains' of patients with Alzheimer’s disease. Cellular models have suggested that this association may be due to the ability of IL-33 to down-regulate A- peptide secretion [11]. A major biological action of this cytokine was recently described as a crucial intracellular nuclear factor with transcriptional regulatory properties associated with Crohn’s disease [12]. All in all, our results showed that there is an association between IL-33 gene polymorphisms and risk of Schizophrenia in our population. However, we suggest that the results of this study be confirmed in further investigations using larger sample size in different populations across the world.
  12 in total

1.  The mouse interleukin (Il)33 gene is expressed in a cell type- and stimulus-dependent manner from two alternative promoters.

Authors:  Dominique Talabot-Ayer; Nicolas Calo; Solenne Vigne; Céline Lamacchia; Cem Gabay; Gaby Palmer
Journal:  J Leukoc Biol       Date:  2011-10-19       Impact factor: 4.962

2.  Increased interleukin-6 level in Taiwanese schizophrenic patients.

Authors:  Chin-Chuen Lin; Chia-Ming Chang; Pi-Yueh Chang; Tiao-Lai Huang
Journal:  Chang Gung Med J       Date:  2011 Jul-Aug

Review 3.  Role of interleukin-33 in innate-type immune cells in allergy.

Authors:  Susumu Nakae; Hideaki Morita; Tatsukuni Ohno; Ken Arae; Kenji Matsumoto; Hirohisa Saito
Journal:  Allergol Int       Date:  2013-03       Impact factor: 5.836

4.  Implication of IL-33 gene polymorphism in Chinese patients with Alzheimer's disease.

Authors:  Jin-Tai Yu; Jing-Hui Song; Nai-Dong Wang; Zhong-Chen Wu; Qun Zhang; Na Zhang; Wei Zhang; Shi-Ying Xuan; Lan Tan
Journal:  Neurobiol Aging       Date:  2010-08-13       Impact factor: 4.673

Review 5.  IL-33 and IL-33 receptors in host defense and diseases.

Authors:  Keisuke Oboki; Tatsukuni Ohno; Naoki Kajiwara; Hirohisa Saito; Susumu Nakae
Journal:  Allergol Int       Date:  2010-04-24       Impact factor: 5.836

6.  Transcriptomic and genetic studies identify IL-33 as a candidate gene for Alzheimer's disease.

Authors:  J Chapuis; D Hot; F Hansmannel; O Kerdraon; S Ferreira; C Hubans; C A Maurage; L Huot; F Bensemain; G Laumet; A M Ayral; N Fievet; J J Hauw; S T DeKosky; Y Lemoine; T Iwatsubo; F Wavrant-Devrièze; J F Dartigues; C Tzourio; L Buée; F Pasquier; C Berr; D Mann; C Lendon; A Alpérovitch; M I Kamboh; P Amouyel; J C Lambert
Journal:  Mol Psychiatry       Date:  2009-02-10       Impact factor: 15.992

7.  Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers.

Authors:  M Maes; E Bosmans; J Calabrese; R Smith; H Y Meltzer
Journal:  J Psychiatr Res       Date:  1995 Mar-Apr       Impact factor: 4.791

Review 8.  The role of interleukin-33 in rhinitis.

Authors:  Barbara Rogala; Joanna Glück
Journal:  Curr Allergy Asthma Rep       Date:  2013-04       Impact factor: 4.806

9.  Role of IL-33 in inflammation and disease.

Authors:  Ashley M Miller
Journal:  J Inflamm (Lond)       Date:  2011-08-26       Impact factor: 4.981

10.  IL-33 reduces the development of atherosclerosis.

Authors:  Ashley M Miller; Damo Xu; Darren L Asquith; Laura Denby; Yubin Li; Naveed Sattar; Andrew H Baker; Iain B McInnes; Foo Y Liew
Journal:  J Exp Med       Date:  2008-02-11       Impact factor: 14.307

View more
  3 in total

Review 1.  Expression and Function of IL-33/ST2 Axis in the Central Nervous System Under Normal and Diseased Conditions.

Authors:  Karen Fairlie-Clarke; Mark Barbour; Chelsey Wilson; Shehla U Hridi; Debbie Allan; Hui-Rong Jiang
Journal:  Front Immunol       Date:  2018-11-20       Impact factor: 7.561

2.  IL-33/ST2 Pathway and Galectin-3 as a New Analytes in Pathogenesis and Cardiometabolic Risk Evaluation in Psychosis.

Authors:  Milica M Borovcanin; Slavica M Janicijevic; Ivan P Jovanovic; Nevena Gajovic; Nebojsa N Arsenijevic; Miodrag L Lukic
Journal:  Front Psychiatry       Date:  2018-06-22       Impact factor: 4.157

Review 3.  Therapeutic Opportunities of Interleukin-33 in the Central Nervous System.

Authors:  Yun Sun; Yankai Wen; Luxi Wang; Liang Wen; Wendong You; Shuang Wei; Lin Mao; Hao Wang; Zuobing Chen; Xiaofeng Yang
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.